Novo Nordisk faces potential layoffs after a period of rapid expansion fueled by the success of Wegovy. The company's ...

The move is likely part of the company’s goal to reduce costs as it faces increased competition in the GLP-1 space.

Wegovy-maker NovoNordisk has implemented a global hiring freeze covering job roles that are not critical for its business, the company said today.

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...

Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

Novo Nordisk is to freeze hiring in an effort to control costs at the drug maker. The halt will apply across all markets and ...

Novo Nordisk may pursue layoffs as its new CEO focuses on efficiency while facing intensifying obesity drug competition.

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

The regulator in its health alert letter mentioned that these stolen drugs are rDNA injectables that require strict ...

“Semaglutide has been in the US for more than eight years now. In India also, the oral version of this molecule is there for ...

Novo Nordisk's economic moat is eroding due to increased competition and US drug price pressures, but growth in international ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...